Related Experiment Video
Updated: Mar 11, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
The role of GATA2 in lethal prostate cancer aggressiveness
Veronica Rodriguez-Bravo1,2, Marc Carceles-Cordon1, Yujin Hoshida2
1Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
Abstract:
Advanced prostate cancer is a classic example of the intractability and consequent lethality that characterizes metastatic carcinomas. Novel treatments have improved the survival of men with prostate cancer; however, advanced prostate cancer invariably becomes resistant to these therapies and ultimately progresses to a lethal metastatic stage. Consequently, detailed knowledge of the molecular mechanisms that control prostate cancer cell survival and progression towards this lethal stage of disease will benefit the development of new therapeutics. The transcription factor endothelial transcription factor GATA-2 (GATA2) has been reported to have a key role in driving prostate cancer aggressiveness. In addition to being a pioneer transcription factor that increases androgen receptor (AR) binding and activity, GATA2 regulates a core subset of clinically relevant genes in an AR-independent manner. Functionally, GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 has a multifaceted function in prostate cancer aggressiveness and is a highly attractive target in the development of novel treatments against lethal prostate cancer.
Insights
Advanced prostate cancer (PCa) cell survival and progression are driven by GATA2. Targeting GATA2 may offer new therapeutic strategies for lethal metastatic PCa.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Advanced prostate cancer (PCa) is a lethal metastatic carcinoma.
- Current treatments improve survival but resistance invariably develops.
- Understanding molecular drivers of PCa progression is crucial for new therapies.
Purpose of the Study:
- To investigate the role of GATA2 in prostate cancer aggressiveness.
- To explore GATA2's mechanisms in AR-dependent and independent pathways.
- To evaluate GATA2 as a therapeutic target for lethal PCa.
Main Methods:
- Analysis of GATA2's role as a transcription factor in PCa.
- Investigating GATA2's impact on AR binding and activity.
- Assessing GATA2's regulation of AR-independent genes.
- Evaluating functional consequences of GATA2 overexpression in PCa cells.
Main Results:
- GATA2 overexpression drives PCa aggressiveness.
- GATA2 enhances AR binding and activity.
- GATA2 regulates key genes independently of AR.
- Overexpressed GATA2 increases PCa cell motility, invasiveness, proliferation, and therapy resistance.
Conclusions:
- GATA2 plays a multifaceted role in prostate cancer progression and lethality.
- GATA2 is a promising therapeutic target for advanced and lethal prostate cancer.
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

